P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial

Cao, F.; Ma, Z.; Hu, G.; Zhu, X.; Li, S.; Chen, Siteng; Chen, B.; Li, Z.; Wu, W.; Ji, X.; Shu, J.; Tao, Danping; Hu, X.; Zheng, Meng; Wang, O.; Feng, Qiaoli; Hao, Jia-Yu; Li, Xuezhong

doi:10.1016/s0960-9776(23)00123-6

Public

P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial

Published in The Breast • Mar 14, 2023

Authors:

F. Cao

Z. Ma

G. Hu

Abstract

Secondary objectives will include assessment of demographic and tumor characteristics, treatment compliance and switching, DFS, OS, safety parameters, additional QoL parameters, and hormone levels (estrone, estradiol, and follicle-stimulating hormone) as a measure of Ovarian Function Suppression (OF...

Subject

Medicine

Trastuzumab

Open label

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!